Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years by Creighton, Prudence et al.
RESEARCH ARTICLE Open Access
Cervical cancer screening in Australia: modelled
evaluation of the impact of changing the
recommended interval from two to three years
Prudence Creighton
1,6, Jie-Bin Lew
1, Mark Clements
2, Megan Smith
1, Kirsten Howard
3, Suzanne Dyer
4,
Sarah Lord
3,4, Karen Canfell
1,5*
Abstract
Background: The National Cervical Screening Program in Australia currently recommends that sexually active
women between the ages of 18-70 years attend routine screening every 2 years. The publically funded National
HPV Vaccination Program commenced in 2007, with catch-up in females aged 12-26 years conducted until 2009;
and this may prompt consideration of whether the screening interval and other aspects of the organized screening
program could be reviewed. The aim of the current evaluation was to assess the epidemiologic outcomes and cost
implications of changing the recommended screening interval in Australia to 3 years.
Methods: We used a modelling approach to evaluate the effects of moving to a 3-yearly recommended screening
interval. We used data from the Victorian Cervical Cytology Registry over the period 1997-2007 to model
compliance with routine screening under current practice, and registry data from other countries with 3-yearly
recommendations to inform assumptions about future screening behaviour under two alternative systems for
screening organisation - retention of a reminder-based system (as in New Zealand), or a move to a call-and-recall
system (as in England).
Results: A 3-yearly recommendation is predicted to be of similar effectiveness to the current 2-yearly
recommendation, resulting in no substantial change to the total number of incident cervical cancer cases or
cancer deaths, or to the estimated 0.68% average cumulative lifetime risk of cervical cancer in unvaccinated
Australian women. However, a 3-yearly screening policy would be associated with decreases in the annual number
of colposcopy and biopsy procedures performed (by 4-10%) and decreases in the number of treatments for pre-
invasive lesions (by 2-4%). The magnitude of the decrease in the number of diagnostic procedures and treatments
would depend on the method of screening organization, with call-and-recall screening associated with the highest
reductions. The cost savings are predicted to be of the order of A$10-18 M annually, equivalent to 6-11% of the
total cost of the current program (excluding overheads), with call-and-recall being associated with the greatest
savings.
Conclusions: Lengthening the recommended screening interval to 3 years in Australia is not predicted to result in
increases in rates of cervical cancer and is predicted to decrease the number of women undergoing diagnostic
and treatment procedures. These findings are consistent with a large body of international evidence showing that
screening more frequently than every three years with cervical cytology does not result in substantial gains in
screening effectiveness.
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The National Cervical Screening Program in Australia
was introduced in 1991, and has been very successful in
reducing the incidence and mortality from cervical
cancer. The program recommends 2-yearly screening
for sexually active women aged from 18-20 to 69 years
[1]. This interval is shorter than that suggested by the
International Agency for Research on Cancer (IARC),
which recommends a 3-yearly screening interval for
women aged 25-49 and a 5-yearly interval for women
aged 50-65 years [2]. When trends in cervical cancer
incidence and mortality in Australia were compared
with those in England, similar reductions were observed
after the introduction of organised screening in each
country, despite the recommended 3-yearly interval that
was in place in many regions in England prior to 2003;
demonstrating that the 2-yearly policy in Australia has
been of broadly similar effectiveness to a predominantly
3-yearly policy in the UK [3].
Australia initiated a national human papillomavirus
(HPV) public vaccination program in 2007, and this
included a two year catch-up phase for females aged 12-
26 years. Although final coverage estimates for the GP-
based component of the catch-up program in older
females have not yet been released, early indications are
that coverage rates in this group are likely to be rela-
tively high [4,5]. Ecological data already indicate a falling
incidence in genital warts in young Australian females,
w h i c hi sl i k e l yt ob ed u et or o l l - o u to faq u a d r i v a l e n t
vaccine that also protects against HPV types 6 and 11,
which are implicated in the development of genital
warts [4,5]. As the vaccinated cohorts mature, cervical
screening will inevitably become less cost-effective over
time, because the average risk of cervical cancer in the
Australian population will eventually fall due to vaccina-
tion. In this context, measures to increase the efficiency
of screening are of interest. In the current evaluation we
took a near term approach and did not explicitly incor-
porate the effect of vaccination on the cost-effectiveness
of 3-yearly screening; rather, the changes in cancer out-
comes and cost-effectiveness associated with a move to
3-yearly screening in the current evaluation should be
considered “worst case” f r o mas a f e t yp e r s p e c t i v e( s i n c e
vaccination will eventually reduce the risk of invasive
cervical cancer in the population).
The National Cervical Screening Program in Australia
uses a reminder-based system, in which women who are
registered on state or territory cytology registries are
s e n tal e t t e ri ft h e yd on o th a v eas c r e e n i n gt e s ta tt h e
recommended interval. We have previously suggested
that if the recommended screening interval is increased,
a move to a call-and-recall system (in which proactive
invitations to attend screening are issued) could be
considered in order to increase compliance with the
new recommendation and to limit late re-screening [6].
The use of a call-and-recall system in England, and
other differences in the organisation of screening, have
been associated with a higher degree of compliance with
the recommended interval in England compared to Aus-
tralia [3].
The objective of the current evaluation was to assess
the epidemiologic outcomes and cost-effectiveness
implications of changing the recommended screening
interval in Australia to 3 years, under two alternative
assumptions about screening organisation - retention of
the current reminder-based system, or a move to call-
and-recall organisation. Specifically, the aims of the
study were to quantify the predicted effect of a 3-yearly
screening recommendation in Australia on: (1) national
rates of invasive cervical cancer cases and cancer deaths;
(2) the estimated average cumulative lifetime risk of cer-
vical cancer in Australian women; (3) the annual num-
ber of colposcopy and biopsy procedures nationally; (4)
the number of treatments for pre-invasive lesions
nationally; and (5) costs and cost-effectiveness. We used
screening registry data from the UK to inform compli-
ance assumptions in Australia if a move to a 3-yearly
recommendation was also associated with a move to
call-and-recall organisation. Because the New Zealand
(NZ) national cervical screening program recommends a
3-yearly interval but uses a reminder-based system, we
used screening registry data from NZ to inform 3-yearly
compliance assumptions if the reminder-based system
was retained in Australia.
Methods
Model construction
A schematic diagram of the model is provided in Figure 1;
details of model structure, calibration and validation have
been described elsewhere [6-10]. Briefly, cervical screen-
ing was simulated using a discrete time, deterministic
Markov cohort model of the natural history of oncogenic
HPV infection, cervical intraepithelial neoplasia (CIN)
and cervical cancer which was integrated with a detailed
decision tree of screening according to current manage-
ment and treatment guidelines in Australia [1]. The
simulation follows a cohort of women from ages 10 to
84. The age-specific incidence of HPV was obtained
from a dynamic model of sexual behaviour and HPV
transmission in Australia [10], and for this study it was
assumed that the HPV incidence reflected an unvacci-
nated cohort.
Screening structures and parameters included: detailed
characterisation of the age distribution of starting
screening in the population (screening initiation) and
age-specific compliance with current screening and all
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information; the results of a systematic review on cytol-
ogy test accuracy [8], analysis of biopsy rates and colpo-
scopy-histology correlation rates from a large database
involving over 21,000 examinations conducted between
1998 and 2007 at the Royal Women’s Hospital, Mel-
bourne (described in [11,12]); treatment compliance and
efficacy, post-treatment management and test-of-cure;
stage-specific cervical cancer survival using registry data
from the state of New South Wales (NSW); hysterect-
omy rates; and costs.
The natural history model of CIN and invasive cervi-
cal cancer was updated from an earlier implementation
[7]. Feasible ranges for natural history transitions were
assessed via literature review and the baseline values
were then calibrated to reproduce cervical cancer inci-
dence in unscreened populations. When complete
screening and management structures were included,
the model was calibrated to reproduce age-specific Aus-
tralian data on HPV prevalence, screen-detected and
histologically-confirmed high grade CIN, and cancer
incidence and mortality rates [8,9] (subsequently, some
parameter changes were made to accommodate the
further calibration target of the age-specific stage distri-
bution of cervical cancer at diagnosis; this did not have
a substantial effect on the predicted lifetime costs and
effects). When the age-specific event rates predicted by
the model of current screening were applied to the 2007
Australian population, model predictions were con-
firmed to broadly concur with recent observed data for
the predicted observed annual numbers of incident cer-
vical cancer cases and cancer deaths and the number of
cytological smears occurring annually in the cervical
screening program (including all smears taken for
screening, follow-up and as part of subsequent pre-and
post-treatment management - ~2 million smears). The
total annual costs of the cervical screening program,
including all follow-up and diagnostic tests and the
costs of managing invasive cervical cancer (but exclud-
ing overheads) was estimated as approximately
$A166 M [8,9].
Under current management guidelines in Australia,
women with high grade cytological results are directly
referred to colposcopy but women with possible and
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Figure 1 Schematic diagram of model structure.
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the Australian Modified Bethesda System and broadly
equivalent to ASCUS and LSIL in The Bethesda System
2001) are followed up at 12 months with repeat cytol-
ogy, unless the women is over 30 years of age without a
recent history of normal cytology. In our evaluation
these follow-up visits were explicitly modelled to take
into account any progression or regression of disease
during the follow-up period. The systematic review of
cytology test accuracy, in conjunction with the observed
laboratory “call” rates for low and high grade lesions in
Australia, was used to estimate the point on the cytol-
ogy receiver operating curve at which laboratories in
Australia are operating (as described in [8]). This infor-
mation was then used to construct a test probability
matrix which described the relationship between each
underlying natural history health state in the model and
the probability of each possible cytology test result. The
matrix completely describes the assumed test accuracy.
As an example, the baseline cross-sectional sensitivity
described by the matrix for histologically confirmed
high-grade disease (CIN2+) at a cytology low grade
( d L S I L )t h r e s h o l di s7 2 % .H o w e v e r ,i ts h o u l db en o t e d
that this does not describe the effective “operational”
sensitivity of cytology in Australia, which depends on
the specific management guidelines and referral pro-
cesses that we modelled.
The model was implemented in TreeAge Pro 2008
(Release 1.3.2, TreeAge Software, Inc., MA, USA).
Analysis of screening registry data
The baseline model of cervical screening in Australia
incorporated the results of an analysis of approximately
6.3 million satisfactory smears from the Victorian Cervi-
cal Cytology Register from the period 1 Jan 1997-31
Dec 2007. The state of Victoria has about one third of
Australia’s population, and the state’s cervical cytology
registry was the first to be established in Australia.
Using the Victorian data, age-specific re-screening prob-
abilities over time were derived from analysis of data
from ~1.7 million women with a negative smear. Re-
screening probabilities over time were calculated and
stratified by the previous cytological smear result and
the recommended recall timing after the previous test.
Interval-specific re-screening probabilities were calcu-
lated for 10 year age-groups, over a period of 10 years
after the index test. For women who did not re-screen
within 10 years of their last test, annual interval-specific
re-screening probabilities at 10+ years were assumed to
vary with age, decreasing from 30% of those who had
not yet been re-screened (in the age group 15-39 years)
to 5% (ages 70 years or more), to reflect the lower prob-
ability of these underscreened women re-attending for
screening at ages older than the target age group for
screening. Because the degree of loss to follow-up over
period of longer than 10 years is uncertain, these prob-
abilities were varied in sensitivity analysis.
The Victorian registry data provided follow-up dates
by month and year, but we categorised the follow-up
duration according to the time step used by the model;
which is 12 months, except at specific points where nat-
ural history and screening transitions were adjusted to
reflect a 6 month time step to model specific follow-up
pathways as required by the Australian cervical screen-
ing guidelines [1]. For the registry data analysis, we
defined the probability of re-attending for screening in
the first annual time step as attendance from 0-15
months after the index test; the second annual time step
included attendance from 16-30 months after the index
test; and annual time steps thereafter included atten-
dance during consecutive 12 month intervals (31-42
months; 43-54 months, etc.). For analysis of compliance
data in situations where there was a recommended
6 month follow-up interval, the probability of re-atten-
dance at 6 months for modelling purposes was
calculated over the period 0-9 months after the index test.
In order to calculate the re-screening probabilities for
hypothetical 3-yearly screening scenarios in Australia,
we used previously published results for analysis of his-
torical registry data on 3-yearly screening compliance
from England in 2,497 women who had negative smears
over the period 1988-1996 (Oxfordshire) [3] to inform
compliance assumptions given a call-and-recall method
of screening organisation; and analysis of data from ~1.1
million women in NZ who had 3.4 million negative
smears over the period July 1 1995- June 30 2005 to
inform compliance assumptions given a reminder-based
system of organisation. Similar methods for calculating
interval-specific probabilities of re-attending for screen-
ing were applied to the Oxfordshire and NZ registry
data as were used for the Victoria data. However,
because we did not have age-specific data for Oxford-
shire, we scaled the all-ages re-screening probabilities
over time according to age-specific coverage data for
England in 1996 [13] in order to estimate age-specific
re-screening probabilities.
We could not directly apply these re-screening prob-
abilities from other countries to Australia in order to
evaluate the differential effects of implementing 2 and
3-yearly screening recommendations, because the cumu-
lative proportion re-screened over longer periods (at
5 years and at 10 years) differed in each country. If the
data from other countries had been directly applied in
the evaluation, the results would partly reflect country-
specific differences in the behaviour of underscreened
women who had not attended screening for 5 years or
more. Therefore, for the main evaluation we adjusted
the patterns of re-screening behaviour from other
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at 4 years and beyond was the same as currently
observed in Australia. This was done so that any differ-
ences in outcomes between the screening strategies
would reflect differences in re-screening before 4 years
(which was assumed to be the period over which the
main effects on screening behaviour of a change from a
2-yearly to a 3-yearly recommendation would be
observed), rather than differences that occur between
settings in re-screening patterns over longer periods of
follow-up. Additionally, because NZ has a slightly higher
level of early rescreening in the first year compared to
Australia, and since we would not expect lengthening
the recommended interval in Australia to be associated
with increased levels of early re-screening in the first
year, we also adjusted the re-screening probabilities
from NZ so that re-screening behaviour in the first year
was the same as currently observed in Australia. We
then populated the model with the re-screening prob-
abilities derived from the England and NZ data to simu-
late the two different 3-yearly screening strategies in
Australian context.
As a secondary analysis we also assessed the cost-
effectiveness of screening if compliance were exactly as
observed in the other countries, even in underscreened
women. We also explored the effects of different
assumptions about early re-screening rates on the cost-
effectiveness outcomes.
In the evaluation we assumed that the current Aus-
tralian screening and management guidelines, and
compliance to these guidelines, would remain
unchanged in every respect other than in relation to
routine screening behaviour in women with normal
(negative) cytology results. For both call-and-recall and
reminder-based systems we assumed, according to
standard practice, that a women who re-screens early
and receives a normal screening result is sent her next
invitation and/or reminder letter after the usual
recommended interval has elapsed following the early
re-screening event.
Outcomes evaluation
The outputs of the model included age-specific
predicted rates of cytology test utilisation, colposcopies,
biopsies and treatments for high grade CIN,
cervical cancer incident cases and cancer deaths. Age-
standardised rates of cancer incidence and mortality
were calculated using the 2001 Australian standard
population. The 2007 Australian female resident popula-
tion was then applied to the age-specific rates to esti-
mate annual resource utilisation, including annual
numbers of screening tests, colposcopies, biopsies and
treatments for high grade CIN; and case numbers of
incident cervical cancer and of cancer deaths.
Cost-effectiveness evaluation
We took a health services perspective, considering
screening, diagnosis and treatment costs that would be
billed to the Australian Medicare (government-
reimbursed) system, in accordance with previous evalua-
tions of cervical screening in Australia [8,9]. The model
was populated with cost data from the Medicare Bene-
fits Schedule for screening, diagnostic, and high grade
CIN treatment procedures and the costs of invasive cer-
vical cancer management; [8,9] with the reimbursed cost
of a cytology smear currently being A$19.60. Lifetime
costs and benefits were estimated for each scenario
using standard cohort model methods. In accordance
with standard practice for health economic evaluation of
the incremental costs and effects of new strategies, we
modelled the effect of different screening strategies on a
specific cohort of women; rather than performing multi-
ple cohort evaluation of the effect of changing strategies
for older cohorts within the screening program who
have been previously screened. The calculation of costs
and life years commenced from age 18 (the earliest age
at which screening is recommended to start in Austra-
lia) with discounting at a rate of 5%. Because the evalua-
tion found that the strategies under consideration had
close-to-equivalent effects but were less expensive than
current practice, the calculation of incremental cost-
effectiveness ratios (ICERs) was not meaningful or
appropriate (when the effects of two strategies are
almost equivalent, the calculated ICER approaches infi-
nity); and therefore we presented incremental costs and
health outcomes compared to current practice in a dis-
aggregated form.
Sensitivity analysis
Sensitivity analysis was performed to assess the robust-
ness of the findings to the natural history and screening
model parameters. We used a combination of one-way,
and where appropriate, multi-way sensitivity approaches
to analyse predicted effects and costs when subsets of
parameters were varied. For the natural history sensitiv-
ity analysis, we applied alternate natural history para-
meter sets for CIN progression and regression
probabilities, non-symptomatic invasive cancer progres-
sion probabilities and also specifically investigated the
sensitivity of results to doubling and halving the para-
meters describing HPV incidence and progression of
CIN 3 to localised invasive cervical cancer. For the
screening parameters, one-way sensitivity analysis was
performed to assess the sensitivity of results to increased
or decreased early re-screening, age at screening initia-
tion, the rate of cytology unsatisfactory results, colpo-
scopy test accuracy and attendance at colposcopy.
Sensitivity of the results to the assumed test characteris-
tics of cytology was analysed using a multi-way
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described the probability of a particular cytology test
result given an underlying health state; these multiple
parameter sets were derived following systematic review
of the literature on cytology test accuracy and are
described in detail in previous work [8]. Secondary ana-
lysis was also performed to assess sensitivity of predicted
effects and costs to long term coverage parameters (as
informed by the analysis of NZ and UK re-screening
data) and the re-screening probabilities after 10 years
since the last screening test.
Ethical approval
T h en e ws c r e e n i n gr e g i s t r yd a t aa n do t h e rs o u r c e so f
new data used in the model were deidentified, and the
Cancer Council NSW Human Research Ethics Commit-
tee approved the transfer of these datasets to the
researchers and their use in modelled evaluation.
Results
Analysis of screening registry data
The cumulative proportions of women with a negative
smear who were re-screened by time since the index
smear for the three countries are shown in Figure 2.
Overall, the data from Oxfordshire show a high level of
compliance to a recommended 3-yearly interval in the
context of call-and-recall organisation. Compared to
Oxfordshire, data from NZ show a greater level of ear-
lier re-screening in the context of a 3-yearly recommen-
dation; but the median interval at which women were
re-screened was similar (36 months for NZ and 38
months for Oxfordshire). As expected, the median inter-
val at which women are screened in Victoria, Australia
is currently shorter than in the other two countries, at
27 months, reflecting the current 2-yearly screening
recommendation. The finding for Victoria is consistent
with prior work on screening compliance in Australia
showing a median re-screening interval of 27 months in
NSW women with an index normal screening test in
1998 [3].
For the main cost-effectiveness evaluation of 3-yearly
screening in Australia, and based on the data from the
UK and NZ shown in Figure 2, we assumed that if the
current reminder-based system was retained, there
would be approximately 44% early re-screening before
33 months, whereas if a call-and-recall system was
implemented, there would be 11% early rescreening
before 33 months.
Outcomes evaluation
Table 1 shows the observed case numbers and rates of
cervical cancer and cervical cancer deaths in Australia,
compared to baseline model predictions for current
practice using the screening data from Victoria to
model current levels of compliance to screening and
management recommendations (baseline predictions
were calibrated to the observed age-specific rates [8,9]).
The model predicts no substantial change in the average
cumulative lifetime risk of cervical cancer in Australian
women (~0.68%) if 3-yearly screening were to be imple-
mented under either a reminder-based or call-and-recall
system. A total of 736 incident cases are predicted
annually for 2-yearly screening; 732 for 3-yearly screen-
ing with a reminder-based system; and 731 for 3-yearly
screening with call-and-recall organisation. A total of
208 cervical cancer deaths are predicted annually for
2-yearly screening; 205 for 3-yearly screening with a
reminder-based system; and 204 for 3-yearly screening
with call-and-recall organisation. Therefore, the number
of cancers and cancer deaths were broadly similar for all
scenarios, with the magnitude of the predicted differ-
ences between strategies being less than the relatively
small difference between baseline predictions for cancer
incidence and mortality and the observed data. Because
of the counter-intuitive baseline finding that 3-yearly
screening had very slightly improved outcomes than
2-yearly screening, we performed further investigation of
the reason for this effect, finding that it was due to
complex issues of modelling the timing of re-screening
in women still not screened after 4 years, in repeated
rounds of screening. We also performed extensive sensi-
tivity analysis to characterise this effect under different
assumptions about late re-screening, as described in
detail in the Sensitivity Analysis section of our results.
Figure 2 Cumulative proportion of women with a negative
smear re-screened over time in Australia, NZ and the UK.
Australian data are for 1.7 million women listed on the Victorian
Cervical Cytology Registry who had a negative smear between 1997
and 2007. NZ data are for 1.1 million women listed on the NZ
National Cervical Screening Registry who had a negative smear
between 1995 and 2005. UK data are for 2,497 randomly selected
Oxfordshire participants in the Million Women Study who had a
negative smear between 1988 and 1996 [3].
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implications of the new screening strategies. Compared
to current practice, a move to a 3-yearly recommenda-
tion would reduce the annual number of cervical
smears, and also reduce the number of colposcopies,
biopsies and treatments occurring within the program.
The reductions would be greater for the call-and-recall
strategy, due to increased compliance to the 3-yearly
interval and consequently lower levels of early re-screen-
ing. The model predicts that a move to 3-yearly screen-
ing in Australia would reduce the annual numbers of
cytology tests by 7-13%, depending on whether call-or-
recall or reminder-based organisation was used (with
the reduction ranging from 7-18% in sensitivity analysis).
The number of colposcopies and biopsies would be
reduced by 4-10% (ranging from 3-13% in sensitivity
analysis), and the number of treatments would be
reduced by 2-4% (ranging from 1-6% in sensitivity analy-
sis). In the baseline model, this is equivalent to between
140,000-250,000 fewer cytology tests, between 2,700-
6,400 fewer colposcopies, between 1,400-3,200 fewer
biopsies, and between 300-600 fewer treatments for high
grade CIN2/3.
Cost-effectiveness evaluation
Figure 3 shows the position on the cost-effectiveness
plane of the screening strategies evaluated. Compared to
current practice, the main 3-yearly screening strategies
under consideration are associated with close-to-equivalent
effectiveness in terms of life years saved by cervical cancer
screening, consistent with the findings reported in Table 1
that the 3-yearly screening strategies are not expected to
increase the number of cervical cancer cases or deaths.
Table 3 shows the costs and effectiveness implications of
the main strategies.
A ss h o w ni nF i g u r e3a n dT a b l e3 ,t h e3 - y e a r l y
screening strategies would be associated with a reduc-
tion in costs to the health care system, with no substan-
tial change in health outcomes, thereby presenting
better value for money than the current program. A
substantial component of the cost saving would result
from the reduction in direct costs of cytology testing
Table 1 Observed and predicted health outcomes in Australia
Cervical cancer
cases
(1)
Cervical cancer incidence per
100,000
(2)
CLR
(3) cervical
cancer
Cervical cancer
deaths
(1)
Cervical cancer mortality per
100,000
(2)
Observed
(4) 723 6.8 – 219 1.9
Current practice,
2-yearly
recommendation
736 6.8 0.68% 208 1.9
Continue reminder
system,
3-yearly
recommendation
732 6.7 0.67% 205 1.8
Call-and-recall,
3-yearly
recommendation
731 6.7 0.67% 204 1.8
Notes
(1) Model-predicted cases and deaths in women aged 0-84 years are estimated using the resident Australian female population in 2007.
(2) Age-standardised to the 2001 Australian population.
(3) CLR = cumulative lifetime risk
(4) Average 2004-2006 [21]
Table 2 Predicted health resources utilisation in Australia
(1)
Total cytology tests
(and change from current
practice)
Total colposcopies
(and change from current
practice)
Total biopsies
(and change from current
practice)
Total CIN 2/3 treatments
(and change from current
practice)
Current practice,
2-yearly
recommendation
1.90M 66,000 32,000 17,600
Continue reminder
system,
3-yearly
recommendation
1.76M
(140,000 fewer)
63,300
(2,700 fewer)
30,600
(1,400 fewer)
17,300
(300 fewer)
Call-and-recall,
3-yearly
recommendation
1.65M
(250,000 fewer)
59,600
(6,400 fewer)
28,800
(3,200 fewer)
17,000
(600 fewer)
Note: (1) Estimated for women of all ages using the resident Australian female population in 2007.
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reduction in the numbers of diagnostic and treatment
procedures. The cost savings are predicted to be of the
order of A$10 M -$18 M annually, equivalent to 6-11%
(range ~5-15% in sensitivity analysis) of the total cost of
the current program, depending on the method of
screening organisation, with call-and-recall being
associated with the greatest savings (although any addi-
tional overhead costs associated with call-and-recall are
not considered in the current evaluation). Under all
strategies, direct cytology costs would be associated with
approximately 22% of the overall costs of the program
(not including overheads). As previously discussed,
ICERs for the new strategies vs. current practice would not
be meaningful due to their very similar effectiveness. How-
ever, Table 3 gives an estimate of the cost-effectiveness
ratio of each strategy compared to no screening interven-
tion (in which the costs involved for the hypothetical strat-
egy of no screening would result from treatment of
invasive cervical cancer). This suggests that the
current screening program is cost-effective, with a cost-
effectiveness ratio compared to no intervention of $35,000
per life year saved, but also that cost-effectiveness would
be improved if the 3-yearly screening strategies were
implemented.
Figure 3 also shows the cost-effectiveness findings for
the supplementary 3-yearly screening strategies that
were evaluated in secondary analysis. These supplemen-
tary evaluations assumed that screening compliance was
exactly as observed in the reference countries of NZ and
the UK, even for women who had not re-screened for 4
years or more after an index negative smear. Because
the data from Oxfordshire show very high levels of re-
screening by 5 years (which is likely related to practi-
tioner incentives structure around 5-yearly coverage
rates in the UK [3]), the overall effectiveness of screen-
ing is increased compared to the other strategies evalu-
ated. Figure 3 also shows the effect of alternate
assumptions about early rescreening in context of the
UK and NZ re-screening behaviour. As expected, as
early rescreening before 3 years decreases, the costs of
the screening program decrease but there is very little
impact on effectiveness.
Figure 3 Cost-effectiveness of current practice with 2-yearly
screening and of potential 3-yearly screening strategies in
Australia. The positions on the cost-effectiveness plane of the main
screening strategies for the evaluation are indicated with solid
symbols. These strategies had equivalent compliance in
underscreened women (equivalent levels of re-attendance after
4 years from the last screening test were assumed). Open symbols
indicate position on the cost-effectiveness plane if screening
compliance was exactly as observed in NZ and the UK, even at
periods greater than 4 years. Strategies marked E1 and E2 involve
alternate assumptions about early re-screening - E1 indicates that
early re-screening levels at 12 months are equivalent to those
currently observed in Australia, whereas E2 indicates that this level
of rescreening is observed over 24 months (dotted arrows indicate
decreasing levels of early re-screening).
Table 3 Estimated total annual costs and effects of cervical screening in Australia, excluding overheads (all costs in
Australian dollars)
Annual costs to health
care system
Direct cytology cost
component
Discounted
lifetime cost
(5% discount
rate)
Discounted
life-years
(5% discount
rate)
Cost-effectiveness ratio compared
to no intervention
No intervention $34.7M* - $52.1* 18.8619 -
Current practice,
2-yearly
recommendation
$166.7M $37.4 M (22%) $416.7 18.8723 $35,000/LYS
Continue
reminder system,
3-yearly
recommendation
$156.7M $34.4 M (22%) $396.4 18.8723 $33,000/LYS
Call-and-recall,
3-yearly
recommendation
$148.8M $32.3 (22%) $373.8 18.8723 $31,000/LYS
*Estimated cost of cervical cancer treatment in an unscreened population
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Figure 4, 5, 6 summarise the findings of sensitivity ana-
lysis on the predicted incremental costs (Figure 4) and
effects for the 3-yearly screening strategies, compared to
current practice for 2-yearly screening. Effects are pre-
sented in two ways - in terms of life years saved or lost
(Figure 5) and in terms of the relative impact on the
number of cervical cancer cases diagnosed (Figure 6).
Given no changes to survival assumptions, the number
of cancer cases is related to the number of cervical can-
cer deaths, which in turn is directly related to life years
lost. However, as shown in Figure 5 and 6, the relative
ordering of the most influential parameters in the sensi-
tivity analysis can vary somewhat depending on the out-
come measure used.
In general, the predicted costs and effects were most
sensitive to changes to assumptions about re-screening
behaviour in women who were still not re-screened
after 4 years. Because of the counter-intuitive baseline
finding that 3-yearly screening had slightly better out-
comes than 2-yearly screening, we performed extensive
sensitivity analysis involving changing the assumptions
about re-screening practices after 4 years of follow-up;
and we found that the effect could be reversed (i.e.
3-yearly screening became slightly less effective than
2-yearly screening). However even under the most
extreme assumption, in which all women not screened
by 4 years in any strategy were assumed to attend in the
fourth year, the effectiveness outcomes for 3-yearly
screening were similar to those for 2-yearly screening,
with the decrement in average life years in the popula-
tion associated with 3-yearly screening predicted to be
less than 0.001% (Figure 5); corresponding to an
increase in the number of predicted cervical cancer
cases by up to a maximum of ~4% under the most
extreme assumption (Figure 6).
The costs and effectiveness findings were also some-
what sensitive to assumptions about CIN natural history,
including the progression rate from CIN3 to invasive
cervical cancer. The base value for the progression of
CIN3 to invasive cancer in the model is age-specific
(with an age-standardised value of 1.3% per annum for
CIN 3 to invasive cancer); this was set after calibration
to produce appropriate outcomes for age-specific rates
of screen-detected high grade lesions, and invasive
cancer incidence in screened and unscreened
-14% -12% -10% -8% -6% -4%
Cancer survival, time to cure for survivor (5 years vs. 10 years)
Progression of undetected cancer (calibrated baseline 
paramater set vs. alternative parameter set)
Colposcopy age-standardised attendance  (75% vs. perfect )
Unsatisfactoty cytology rate (4.4% vs. 1.1%)
Colposcopy test characteristics (baseline assumption vs. 
perfect accuracy)
CIN3 to invasive cancer progression rate (0.8% p.a. vs. 2.6% 
p.a.)
Cytology test characteristics (various alternate test 
characteristics (2))
Screening initiation ( baseline age-specific initiation vs. all 
commenced at age 20)
Re-screening compliance after 10 years (0.3 p.a. in all ages vs. 
0.3 p.a. in 10-69 years and 0 p.a. in 70+ years)
Re-screening compliance after 5th year (perfect compliance vs. 
baseline assumption)
HPV incidence (halved vs. doubled)
Pre-cancer natural history (less aggressive parameter set vs. 
more aggressive parameter set)
Re-screening compliance after 4th year (perfect compliance vs. 
baseline assumption)
Early re-screening (1)
% Incremental cost
-14% -12% -10% -8% -6% -4%
% Incremental cost
(a)3-yearly recommendation with retention of the 
reminder-based system
(b)3-yearly recommendation with call-and-recall 
organisation
Figure 4 Sensitivity analysis for incremental costs of 3-yearly screening vs. current practice with a 2-yearly recommendation. Note:
(1) When assumptions about early re-screening in both 2 and 3-yearly screening scenarios were varied, the direction of the incremental effect
on 3-yearly screening was different for the two different 3-yearly screening scenarios. For a move to a 3-yearly recommendation with retention
of the reminder-based system, a higher early re-screening rate resulted in an increase in the cost savings; for a move to 3-yearly screening with
call-and-recall organisation a higher early re-screening rate decreased the cost-savings. (2) When cytology test characteristics in 2 and 3-yearly
screening scenarios were varied, the direction of the incremental effect on 3-yearly screening was different for the two different 3-yearly
screening scenarios.
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Page 9 of 14populations [8,9]. The outcomes were also somewhat
sensitive to the assumed HPV incidence, and we
assessed the effect of halving HPV incidence at all ages.
A decrease of this magnitude is expected to occur
within a few years of implementing the National HPV
Vaccination Program [10] (although in practice the
decrease will be concentrated mainly in younger women
rather than immediately observed at all ages). In this
situation the magnitude of downstream cost savings
related to screening, diagnosis and treatment was similar
to the baseline situation (in the baseline evaluation 3-
yearly screening was associated with a 6-11% reduction
in costs, whereas when HPV incidence is halved the
cost reductions ranged from ~4-12%). This implies that
the relative cost savings achieved by changing the
screening program would still apply over the medium
and longer term, taking into account changes of the
magnitude induced by the effect of the National HPV
Vaccination Program on HPV incidence in Australia.
In general, although estimates of absolute resource
utilisation, health outcomes and costs varied with para-
meter variation in sensitivity analysis, the relative differ-
ences between scenarios with 2 and 3-yearly screening
were robust to parameter variation. Under a wide range
of parameter variations, cost savings were achieved and
the predicted relative effectiveness of 2 vs. 3-yearly
screening was close-to-equivalent.
Discussion
This evaluation has found that when realistic levels of
current and future screening compliance are taken into
account, moving to a 3-yearly interval in Australia is not
predicted to have a substantial impact on cervical cancer
incidence and mortality. This finding accords with a
previous evaluation of trends in cervical cancer inci-
dence and mortality in relation to the effect of 2-yearly
screening in Australia and 3-yearly screening in Eng-
land; [3] and also with a large body of global evidence
that suggests that the incremental value of performing
screening more frequently than every 3 years (or more
than every 5 years in women over 50 years of age) is
limited [14,15]. After consideration of the worldwide
evidence, in 2005 the International Agency for Research
on Cancer recommended that screening be conducted
3-yearly in women aged 25-49 years, and 5-yearly in
women aged 50-64 years [2].
A second major finding of this evaluation is that the
implementation of 3-yearly screening is expected to
Colposcopy test characteristics (baseline assumption vs. 
perfect accuracy)
Early re-screening (3)
Colposcopy age-standardised attendance  (75% vs. 
perfect )
Screening initiation ( baseline age-specific initiation vs. 
all commenced at age 20)
Cancer survival, time to cure for survivor (10 years vs. 5 
years)
CIN3 to invasive cancer progression rate (2)
Progression of undetected cancer (alternative 
parameter set vs. calibrated baseline paramater set)
Pre-cancer natural history (less aggressive parameter 
set vs. more aggressive parameter set)
HPV incidence (halved vs. doubled)
Cytology test characteristics (various alternate test 
characteristics (1))
Re-screening compliance after 10 years (0.3 p.a. in all 
ages vs. 0.3 p.a. in 10-69 years and 0 p.a. in 70+ years)
Re-screening compliance after 5th year (perfect 
compliance vs. baseline assumption)
Re-screening compliance after 4th year (perfect 
compliance vs. baseline assumption)
% Incremental  life-years % Incremental life-years
(a)3-yearly recommendation with retention of the 
reminder-based system
(b)3-yearly recommendation with call-and-recall 
organisation
Figure 5 Sensitivity analysis for incremental effect on life years saved or lost with 3-yearly screening vs. current practice with a
2-yearly recommendation. Notes: (1) When cytology test characteristics in 2 and 3-yearly screening scenarios were varied, the direction of the
incremental effect on 3-yearly screening was different for the two different 3-yearly screening scenarios. Similarly, (2) and (3): changing
assumptions about CIN 3 progression to invasive cancer and early re-screening had effects of opposite directions on the two 3-yearly
recommendations.
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Page 10 of 14reduce the number of diagnostic examinations and
treatments conducted within the screening program,
and this effect would be maximised under a call-and-
recall system because of likely increased compliance to
the new interval. Taken together with our finding that
cervical cancer rates are not predicted to substantially
change in context of 3-yearly screening, this implies that
3-yearly screening would be associated with a greater
efficiency in referring the appropriate women for diag-
nostic evaluation. The reductions predicted in the num-
ber of treatments for high grade precancer is an
important benefit associated with increasing the recom-
mended screening interval, especially in women of
reproductive age. This is because such treatments are
associated with an increased risk of obstetric complica-
tions, including pre-term delivery, low birth weight and
premature rupture of the membranes [16] and for some
treatment modalities, increased perinatal mortality and
other serious pregnancy outcomes [17]. Our baseline
findings predict that 300-600 fewer women in Australia
would undergo such treatments each year under a 3-
yearly recommendation.
A substantial body of evidence has now found that
screening in women younger than 25 years of age does
not substantially lower the risk of developing invasive
cervical cancer, and this evidence has been critical in
informing the IARC recommendations for screening [2].
We have previously proposed that a change to the
recommended age of starting screening to age 25 years
could be evaluated in Australia [6]. In the current eva-
luation, we have not explicitly considered the impact of
raising the age of starting screening, but it will be a
focus of future work, particularly in the context of HPV
vaccination and of potential changes to the primary
screening technology. It should be noted that organiza-
tional aspects of screening are also expected to be
i m p o r t a n ti ns u c ha ne v a l u a t i o n ;s i n c et h et i m i n go f
screening initiation is likely to depend on whether
women are specifically invited to attend for screening at
age 25 years.
Our analysis has several limitations. Firstly, we did not
explicitly model the impact of HPV vaccination on the
risk of disease in younger cohorts of females. However,
we did assess the effect of reduced HPV incidence in
sensitivity analysis, and as discussed, from a safety per-
spective the current evaluation provides a “worst case”
outcome since the overall risks of cervical cancer in the
population will eventually reduce in the context of HPV
vaccination. Future work will explicitly evaluate the
cost-effectiveness of changes to the screening program
-2% -1% 0% 1% 2% 3% 4%
Cancer survival, time to cure for survivor (5 years vs. 10 
years)
HPV incidence (halved vs. doubled)
Colposcopy test characteristics (perfect accuracy vs. 
baseline assumption)
Progression of undetected cancer (calibrated baseline 
paramater set vs. alternative parameter set)
Pre-cancer natural history (less aggressive parameter set 
vs. more aggressive parameter set)
Colposcopy age-standardised attendance  (perfect  vs. 
75%)
Screening initiation (all commenced at age 20 vs.  baseline 
age-specific initiation)
Early re-screening (2)
CIN3 to invasive cancer progression rate (0.8% p.a. vs. 
2.6% p.a.)
Cytology test characteristics (various alternate test 
characteristics (1))
Re-screening compliance after 10 years (0.3 p.a. in 10-69 
years and 0 p.a. in 70+ years vs. 0.3 p.a. in all ages)
Re-screening compliance after 5th year (baseline 
assumption vs. perfect compliance)
Re-screening compliance after 4th year (baseline 
assumption vs. perfect compliance)
% Incremental  cancer  cases
-2% -1% 0% 1% 2% 3% 4%
% Incremental  cancer cases
(a)3-yearly recommendation with retention of the 
reminder-based system
(b) 3-yearly recommendation with call-and-recall 
organisation
Figure 6 Sensitivity analysis for incremental numbers of cervical cancer cases diagnosed with 3-yearly screening vs. current practice
with a 2-yearly recommendation. Notes: (1) When cytology test characteristics in 2 and 3-yearly screening scenarios were varied, the direction
of the incremental effect on 3-yearly screening was different for the two different 3-yearly screening scenarios. (2) Assumptions about early re-
screening had effects of opposite directions on the two 3-yearly recommendations.
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Page 11 of 14in the context of vaccination, using multiple cohort
modelling methods. Secondly, we did not include any
overhead costs involved in setting up call-and-recall
screening, and if this organisational change were to be
made this overhead cost would need to be considered.
A further limitation of the study is the use of historical
data to inform assumptions about future screening com-
pliance. We analysed screening and management compli-
ance over periods of 10 years after the last test, which
required that we use data on 10 or more years of follow-
up. However, some aspects of screening behaviour are
changing over time in Australia - for example, recent
data from the National Cervical Screening Program indi-
cates that rates of early re-screening before 21 months
are reducing and 5-yearly coverage rates are increasing
[18]. However, our evaluation demonstrates that early re-
screening has little impact on the effectiveness of screen-
ing, and the evaluation of UK re-screening behaviour
demonstrates that high rates of 5-yearly coverage (for
women not re-screened by 3 years) increases the overall
effectiveness of screening. Therefore, the recent trends in
the behaviour of Australian women should have a neutral
or positive effect for the effectiveness of screening; again,
this implies that our analysis provides a “worst case” esti-
mate of outcomes from a safety perspective. Another
issue is that it is unlikely that the screening compliance
in Australia under new 3-yearly recommendations would
precisely mirror that in other countries, because it is
likely that there are other aspects of screening organisa-
tion and/or geographic issues that would influence
screening compliance in Australian context. Therefore,
our findings should be seen as indicative of potential out-
comes in context of a move to 3-yearly screening, where
the actual outcomes would be conditional on behaviour
in relation to screening compliance.
Our evaluation predicts a reduction in the number of
treatments for high grade lesions conducted when 3-
yearly screening is recommended. This is likely to be
due to the longer screening interval allowing a greater
fraction of high grade cases to regress naturally, whilst
maintaining a similar detection rate for those high grade
lesions that would have progressed to invasive cervical
cancer. Our prediction of a reduced number of high
grade treatments in the National Cervical Screening
Program is broadly consistent with the findings of a
prior analysis of NSW registry data, which predicted a
statistically non-significant decrease in histologically-
confirmed high grade cases, and a significant decrease in
rates of high grade cytology, in the context of 3-yearly
screening [19]. However, the estimates from this prior
study are not directly comparable to the current evalua-
tion because we considered the overall effects of lifetime
screening behaviour in the entire population; whereas
the prior study estimated the increased risk of a high
grade according to screening interval in women with 2
or more cytology tests (conditional on the first test hav-
ing a negative result), and applied these estimates by
pro-rating the 2-yearly participation rate to a 3-yearly
situation. Our overall findings are also broadly consis-
tent with those of another previous modelled evaluation
which examined the effect of changing screening inter-
vals to 3 years in Australia [20]. Unlike our study, this
evaluation did find that 3-yearly screening would be
associated with a small decrease (<5%) in the total num-
ber of life years saved by the cervical screening program;
but this finding was made in context of assumed current
and future perfect compliance with screening recom-
mendations [20].
To our knowledge, the current evaluation of cervical
screening in Australia is the first conducted in any setting
which takes into account realistic levels of screening com-
pliance in relation to the method of screening organisa-
tion. By harnessing detailed screening program data from
three countries, we have been able to apply information
from other screening programs to inform an assessment
of future screening options in Australia. A move to 3-
yearly screening is predicted to reduce the annual num-
bers of screening tests, diagnostic investigations and treat-
ments for high grade precancers, without resulting in a
substantial increase in incident cervical cancers or cervical
cancer deaths. Various aspects of the National Cervical
Screening Program in Australia could be re-considered
over the next few years as a consequence of several factors,
including the implementation of HPV vaccination, the
availability of new cytology screening technologies and the
potential role of primary HPV DNA testing for cervical
screening. The current evaluation provides a basis for
future assessments, which will also involve consideration
of further extensions to the screening interval in the con-
text of primary HPV testing.
Conclusion
This evaluation suggests that the recommended screen-
ing interval can be safely extended from 2 to 3 years in
Australia. This finding accords with the worldwide evi-
dence on the optimal screening interval for cervical can-
cer screening with cervical cytology. We have quantified
in detail the implications for the National Cervical
Screening Program in Australia; giving predicted out-
comes in context of retention of the current reminder-
based system of screening organisation, or in context of
a move to call-and-recall screening. In either case, a
recommended 3-yearly interval is predicted to reduce
the burden of diagnostic tests and treatments for high
grade precancer, without resulting in a substantial
increase in cervical cancer cases or deaths.
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